Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.32 |
| ▸ | GABRD | O14764 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788324 | 0.98 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRBSLC1A3SLC1A2 | |
| SCHEMBL19852653 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TSHRTHRB | |
| SCHEMBL303947 | 0.79 | — | — | |
| SCHEMBL780052 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRTHRB | |
| SCHEMBL1172448 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRTHRB | |
| SCHEMBL10808653 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRTHRB | |
| SCHEMBL2329737 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRBNOS3NOS1 | |
| SCHEMBL6363592 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL30065241 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL16246663 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283830-A1 | COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2017-10-05 | — | — | US | claimed |
| WO-2016207779-A1 | IMMUNOGENIC SYNTHETIC OLIGOPEPTIDES | STRELNIKOV, Evgeny (RU) | 2016-12-29 | — | — | WO | claimed |
| WO-2016207782-A1 | IMMUNOGENIC SYNTHETIC OLIGOPEPTIDES FOR A VACCINE AGAINST HIV | STRELNIKOV, Evgeny (RU) | 2016-12-29 | — | — | WO | claimed |
| WO-2016207781-A1 | IMMUNOGENIC SYNTHETIC OLIGOPEPTIDES FOR A VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS | STRELNIKOV, Evgeny (RU) | 2016-12-29 | — | — | WO | claimed |
| EP-3108896-A1 | IMMUNOGENIC SYNTHETIC OLIGOPEPTIDES | Spinosa, Jean-Pierre (CH) | 2016-12-28 | — | — | EP | claimed |
| WO-2010123983-A1 | COMPOSTIONS AND METHODS FOR TARGETED GENE THERAPY | YALE UNIVERSITY (US) | 2010-10-28 | — | — | WO | claimed |
| US-20260021194-A1 | ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD | LILLY CO ELI (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250332277-A1 | PROTEIN TYROSINE KINASE 7 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | LILLY CO ELI (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025227010-A1 | PROTEIN TYROSINE KINASE 7 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ELI LILLY AND COMPANY (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12419964-B2 | Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload | ELI LILLY AND COMPANY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250127916-A1 | ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD | ELI LILLY AND COMPANY | 2025-04-24 | — | — | US | disclosed |
| US-20250122239-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2025-04-17 | — | — | US | disclosed |
| WO-2025073812-A1 | ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD | ELI LILLY AND COMPANY (DE) | 2025-04-10 | — | — | WO | disclosed |
| EP-1904079-A2 | PEPTIDE NUCLEIC ACID PROBES FOR ANALYSIS OF MICROORGANISMS | AdvanDx, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007081792-A2 | METHODS AND COMPOSITIONS RELATED TO IMPROVING PROPERTIES OF PHARMACOLOGICAL AGENTS TARGETING NERVOUS SYSTEM | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2006130872-A2 | PEPTIDE NUCLEIC ACID PROBES FOR ANALYSIS OF MICROORGANISMS | ADVANDX, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-7060432-B1 | contacting a yeast sample with yeast specific enzyme-linked probes, hybridizes to form probe/target sequence within; for analysis of beer and liquor | APPLERA CORPORATION (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050054836-A1 | Chimeric molecules to modulate gene expression | COLD SPRING HARBOR LABORATORY | 2005-03-10 | — | — | US | disclosed |
| EP-1416972-A2 | CHIMERIC MOLECULES TO MODULATE GENE EXPRESSION | COLD SPRING HARBOR LABORATORY (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2002038738-A2 | CHIMERIC MOLECULES TO MODULATE GENE EXPRESSION | COLD SPRING HARBOR LABORATORY (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419964-B2 | Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload | NECTIN4, SDC4, EPCAM | ALDH1A1 1777/4885TSHR 1104/4885THRB 2649/4885 |
| US-20170283830-A1 | COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF | ZFX, ATR, CHEK1 | ALDH1A1 3353/4885TSHR 3421/4885THRB 2235/4885 |
| US-20250332277-A1 | PROTEIN TYROSINE KINASE 7 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | PTK2B, PTK2, ERBB2 | ALDH1A1 3955/4885TSHR 1806/4885THRB 2257/4885 |
| US-20260021194-A1 | ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD | NECTIN4, FCGR2A, FCGR3B | ALDH1A1 3360/4885TSHR 113/4885THRB 1556/4885 |
| US-20050054836-A1 | Chimeric molecules to modulate gene expression | MYCBP, IGF2BP1, IGF2BP3 | ALDH1A1 3970/4885TSHR 1898/4885THRB 1004/4885 |
| US-20250127916-A1 | ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD | NECTIN4, SDC4, EPCAM | ALDH1A1 1777/4885TSHR 1104/4885THRB 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.